Theravance Biopharma, Inc. - Common Stock (TBPH) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
TBPH on Nasdaq
Shares outstanding
49,779,938
Price per share
$20.33
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
48,375,344
Total reported value
$706,279,654
% of total 13F portfolios
0%
Share change
+2,403,201
Value change
+$36,991,567
Number of holders
159
Price from insider filings
$20.33
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Theravance Biopharma, Inc. - Common Stock (TBPH) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Newtyn Management, LLC 9.7% $40,580,648 4,757,403 Newtyn Management, LLC 31 Dec 2024
BlackRock, Inc. 6.5% $27,600,487 3,235,696 BlackRock, Inc. 31 Mar 2025

As of 30 Sep 2025, 159 institutional investors reported holding 48,375,344 shares of Theravance Biopharma, Inc. - Common Stock (TBPH). This represents 97% of the company’s total 49,779,938 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Theravance Biopharma, Inc. - Common Stock (TBPH) together control 87% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Madison Avenue Partners, LP 19% 9,511,150 0% 8.3% $138,862,790
Weiss Asset Management LP 15% 7,457,060 0% 1.7% $108,873,076
Newtyn Management, LLC 9.9% 4,950,000 0% 8.8% $72,270,000
BlackRock, Inc. 8.2% 4,068,994 -1.7% 0% $59,407,312
Irenic Capital Management LP 5.5% 2,760,948 0% 7.9% $40,309,841
VANGUARD GROUP INC 4.4% 2,211,582 +2.5% 0% $32,289,097
Park West Asset Management LLC 2.6% 1,284,081 -29% 1.7% $18,747,583
D. E. Shaw & Co., Inc. 2.4% 1,209,312 +21% 0.01% $17,655,955
Oasis Management Co Ltd. 2.2% 1,118,935 0% 2.8% $16,336,451
ACADIAN ASSET MANAGEMENT LLC 2.2% 1,089,381 +253% 0.03% $15,899,000
STATE STREET CORP 2.1% 1,055,905 +2% 0% $15,416,213
GEODE CAPITAL MANAGEMENT, LLC 1.8% 897,990 +0.45% 0% $13,113,478
DIMENSIONAL FUND ADVISORS LP 1.5% 766,704 +6.2% 0% $11,193,148
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.5% 726,783 0.01% $10,611,032
MORGAN STANLEY 1.2% 599,551 +8.9% 0% $8,753,444
BANK OF AMERICA CORP /DE/ 1.1% 527,107 -2.3% 0% $7,695,763
UBS Group AG 1% 514,170 +29% 0% $7,506,883
Assenagon Asset Management S.A. 0.83% 414,715 +1629% 0.01% $6,054,839
BNP PARIBAS FINANCIAL MARKETS 0.75% 373,600 0% 0% $5,454,560
MARSHALL WACE, LLP 0.72% 357,651 +255% 0.01% $5,221,705
NORTHERN TRUST CORP 0.69% 341,306 -3.1% 0% $4,983,068
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.64% 320,144 +5.3% 0% $4,674,102
Hillsdale Investment Management Inc. 0.62% 310,700 0.14% $4,536,220
TANG CAPITAL MANAGEMENT LLC 0.53% 264,308 0% 0.15% $3,858,897
GOLDMAN SACHS GROUP INC 0.52% 258,648 +30% 0% $3,776,261

Institutional Holders of Theravance Biopharma, Inc. - Common Stock (TBPH) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 3,689,317 $69,072,255 +$4,220,036 $18.71 36
2025 Q3 48,375,344 $706,279,654 +$36,991,567 $14.60 159
2025 Q2 46,436,015 $512,193,131 +$17,041,774 $11.03 134
2025 Q1 44,895,013 $400,910,204 +$808,035 $8.93 130
2024 Q4 44,887,720 $422,397,092 -$6,901,386 $9.41 128
2024 Q3 45,764,660 $368,891,620 -$13,802,451 $8.06 118
2024 Q2 47,110,898 $399,555,296 -$8,036,590 $8.48 129
2024 Q1 47,958,440 $430,313,764 -$11,493,088 $8.97 119
2023 Q4 24,036 $270,165 -$27,965 $11.24 1
2023 Q3 50,811,645 $438,505,453 -$16,153,911 $8.63 113
2023 Q2 52,332,937 $541,674,773 -$81,251,938 $10.35 116
2023 Q1 60,151,070 $652,599,949 -$19,312,912 $10.85 112
2022 Q4 62,067,439 $696,143,009 -$39,746,777 $11.22 117
2022 Q3 58,063,670 $588,772,966 -$970,298 $10.14 108
2022 Q2 59,186,445 $536,209,921 +$8,898,180 $9.06 104
2022 Q1 57,971,684 $554,227,380 +$32,330,689 $9.56 111
2021 Q4 52,760,394 $582,792,603 -$17,103,318 $11.05 105
2021 Q3 60,097,309 $444,664,647 -$37,776,662 $7.40 108
2021 Q2 60,695,603 $881,946,201 +$106,303,422 $14.52 101
2021 Q1 53,537,619 $1,092,710,410 +$7,578,886 $20.41 105
2020 Q4 53,176,755 $944,934,510 +$17,421,744 $17.77 101
2020 Q3 52,182,807 $771,533,748 -$4,427,935 $14.78 111
2020 Q2 52,223,921 $1,096,165,885 +$23,328,000 $20.99 117
2020 Q1 55,327,593 $1,278,741,943 +$248,804,406 $23.11 101
2019 Q4 44,808,185 $1,159,626,320 +$117,891,665 $25.89 101
2019 Q3 46,191,630 $899,811,276 -$26,253,876 $19.48 87
2019 Q2 36,303,079 $592,830,501 +$40,021,682 $16.33 91
2019 Q1 48,424,579 $1,097,850,213 +$14,570,521 $22.67 97
2018 Q4 47,693,431 $1,220,447,234 -$165,709 $25.59 92
2018 Q3 47,402,456 $1,548,591,468 +$9,878,401 $32.67 90
2018 Q2 47,820,854 $1,084,572,647 +$18,514,936 $22.68 82
2018 Q1 47,690,819 $1,156,482,841 +$19,338,318 $24.25 84
2017 Q4 46,923,792 $1,308,684,945 -$13,540,256 $27.89 79
2017 Q3 47,312,839 $1,619,998,372 +$33,453,567 $34.24 83
2017 Q2 46,214,826 $1,841,223,924 +$26,493,096 $39.84 90
2017 Q1 45,113,403 $1,660,949,113 +$168,196,264 $36.82 93
2016 Q4 43,770,399 $1,395,386,696 +$264,288,528 $31.88 96
2016 Q3 35,300,039 $1,277,832,411 +$76,633,705 $36.24 99
2016 Q2 33,917,613 $769,608,364 +$131,838,265 $22.69 94
2016 Q1 28,007,024 $526,349,830 +$42,739,768 $18.80 75
2015 Q4 25,920,285 $424,826,625 +$86,183,547 $16.39 77
2015 Q3 20,538,771 $225,713,337 -$24,508,089 $10.99 77
2015 Q2 22,156,314 $288,463,279 +$16,252,972 $13.02 83
2015 Q1 20,882,605 $362,362,742 +$7,466,335 $17.35 82
2014 Q4 20,299,301 $302,904,647 -$33,577,863 $14.92 85
2014 Q3 21,080,115 $486,031,514 +$14,295,064 $23.05 83
2014 Q2 20,187,436 $644,189,482 +$644,125,425 $31.88 87
2014 Q1 842 $14,609 $0 $17.35 1